glycine has been researched along with Myelodysplastic Syndromes in 24 studies
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS)." | 9.16 | Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. ( Groopman, J; Kwak, M; Loeliger, K; Maniar, M; Maric, I; Olnes, MJ; Pfannes, L; Scheinberg, P; Shenoy, A; Sloand, EM; Tian, X; Tucker, Z; Weinstein, B; Wilhelm, F; Yong, AS; Young, NS, 2012) |
| "We previously demonstrated upregulation of c-myc, survivin, and cyclin D1 in CD34+ bone marrow mononuclear cells (BMMNCs) of patients with trisomy 8 and monosomy 7 myelodysplastic syndromes (MDS)." | 5.16 | Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. ( Groopman, J; Kwak, M; Loeliger, K; Maniar, M; Maric, I; Olnes, MJ; Pfannes, L; Scheinberg, P; Shenoy, A; Sloand, EM; Tian, X; Tucker, Z; Weinstein, B; Wilhelm, F; Yong, AS; Young, NS, 2012) |
| "Hypomethylating agents such as 5-azacytidine or decitabine have been a major breakthrough in the treatment of patients with myelodysplastic syndromes (MDS)." | 4.87 | Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. ( Jabbour, E; Kadia, TM; Kantarjian, H, 2011) |
| " Oral roxadustat dosed thrice weekly was well tolerated." | 3.11 | Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study. ( Bartels, P; Bradley, C; Carraway, HE; Glaspy, J; Harrup, R; Henry, DH; Leong, R; Mittelman, M; Modelska, K; Saha, G; Yu, KP; Zhou, A, 2022) |
| " Mean absolute oral bioavailability ranged from 13·9% (fed) to 34·8% (fasting) in 12 patients treated at the 560 mg b." | 2.78 | Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. ( Komrokji, RS; Lancet, JE; List, AF; Maniar, M; Raza, A; Ren, C; Taft, D; Wilhelm, F, 2013) |
| "To identify the maximum-tolerated dose (MTD) and to evaluate the antileukemic activity of tosedostat (formerly CHR-2797), an orally bioavailable aminopeptidase inhibitor." | 2.75 | Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. ( Bone, E; Burnett, AK; Davies, F; Dierickx, D; Dührsen, U; Flores, N; Hooftman, L; Jenkins, C; Krug, U; Löwenberg, B; Morgan, G; Müller-Tidow, C; Ossenkoppele, GJ; Richardson, AF; Sonneveld, P; Zachée, P; Zweegman, S, 2010) |
| "The objective of this review is to evaluate the mechanism of activity, efficacy and dosing of rigosertib." | 2.49 | Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. ( Fan, AC; Felsher, DW; O'Rourke, JJ; Praharaj, DR, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (75.00) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Henry, DH | 1 |
| Glaspy, J | 1 |
| Harrup, R | 1 |
| Mittelman, M | 1 |
| Zhou, A | 1 |
| Carraway, HE | 1 |
| Bradley, C | 1 |
| Saha, G | 1 |
| Modelska, K | 1 |
| Bartels, P | 1 |
| Leong, R | 1 |
| Yu, KP | 1 |
| Patnaik, MM | 1 |
| Santini, V | 2 |
| Navada, SC | 3 |
| Garcia-Manero, G | 3 |
| OdchimarReissig, R | 1 |
| Pemmaraju, N | 1 |
| Alvarado, Y | 1 |
| Ohanian, MN | 1 |
| John, RB | 1 |
| Demakos, EP | 2 |
| Zbyszewski, PS | 3 |
| Maniar, M | 4 |
| Woodman, RC | 1 |
| Fruchtman, SM | 3 |
| Silverman, LR | 6 |
| Platzbecker, U | 4 |
| Lee, S | 1 |
| Desai, P | 1 |
| Edirisinghe, B | 1 |
| Pianello, S | 1 |
| Curcio, T | 1 |
| Samuel, M | 1 |
| Ritchie, EK | 1 |
| Roboz, GJ | 2 |
| Parisi, S | 1 |
| Finelli, C | 1 |
| Fazio, A | 1 |
| De Stefano, A | 1 |
| Mongiorgi, S | 1 |
| Ratti, S | 1 |
| Cappellini, A | 1 |
| Billi, AM | 1 |
| Cocco, L | 1 |
| Follo, MY | 1 |
| Manzoli, L | 1 |
| Jost, M | 1 |
| Chen, Y | 1 |
| Gilbert, LA | 1 |
| Horlbeck, MA | 1 |
| Krenning, L | 1 |
| Menchon, G | 1 |
| Rai, A | 1 |
| Cho, MY | 1 |
| Stern, JJ | 1 |
| Prota, AE | 1 |
| Kampmann, M | 1 |
| Akhmanova, A | 1 |
| Steinmetz, MO | 1 |
| Tanenbaum, ME | 1 |
| Weissman, JS | 1 |
| Odchimar-Reissig, R | 1 |
| Petrone, ME | 1 |
| Holland, JF | 2 |
| Nazha, A | 1 |
| Sekeres, MA | 2 |
| Komrokji, R | 1 |
| Steensma, DP | 2 |
| Kantarjian, H | 3 |
| Roboz, G | 1 |
| Fenaux, P | 2 |
| Prebet, T | 1 |
| Azarnia, N | 2 |
| Balaian, E | 1 |
| Weidner, H | 1 |
| Wobus, M | 1 |
| Baschant, U | 1 |
| Jacobi, A | 1 |
| Mies, A | 1 |
| Bornhäuser, M | 1 |
| Guck, J | 1 |
| Hofbauer, LC | 1 |
| Rauner, M | 1 |
| Komrokji, RS | 1 |
| Raza, A | 2 |
| Lancet, JE | 1 |
| Ren, C | 1 |
| Taft, D | 1 |
| Wilhelm, F | 4 |
| List, AF | 2 |
| Fan, AC | 2 |
| O'Rourke, JJ | 1 |
| Praharaj, DR | 1 |
| Felsher, DW | 2 |
| Greenberg, P | 2 |
| Olnes, MJ | 2 |
| Reddy, P | 1 |
| Xu, F | 1 |
| He, Q | 1 |
| Li, X | 1 |
| Chang, CK | 1 |
| Wu, LY | 1 |
| Zhang, Z | 1 |
| Liu, L | 1 |
| Shi, WH | 1 |
| Zhu, Y | 1 |
| Zhao, YS | 1 |
| Gu, SC | 1 |
| Fei, CM | 1 |
| Guo, J | 1 |
| Wu, D | 1 |
| Zhou, L | 1 |
| Hyoda, T | 1 |
| Tsujioka, T | 1 |
| Nakahara, T | 1 |
| Suemori, S | 1 |
| Okamoto, S | 1 |
| Kataoka, M | 1 |
| Tohyama, K | 1 |
| Mawad, R | 1 |
| Becker, PS | 1 |
| Hendrie, P | 1 |
| Scott, B | 1 |
| Wood, BL | 1 |
| Dean, C | 1 |
| Sandhu, V | 1 |
| Deeg, HJ | 1 |
| Walter, R | 1 |
| Wang, L | 1 |
| Myint, H | 1 |
| Singer, JW | 1 |
| Estey, E | 1 |
| Pagel, JM | 1 |
| Al-Kali, A | 1 |
| Baer, MR | 1 |
| Gaidano, G | 1 |
| Scott, BL | 1 |
| Kambhampati, S | 1 |
| Kreuzer, KA | 1 |
| Godley, LA | 1 |
| Atallah, E | 1 |
| Collins, R | 1 |
| Jabbour, E | 2 |
| Wilhelm, FE | 1 |
| Löwenberg, B | 1 |
| Morgan, G | 1 |
| Ossenkoppele, GJ | 1 |
| Burnett, AK | 1 |
| Zachée, P | 1 |
| Dührsen, U | 1 |
| Dierickx, D | 1 |
| Müller-Tidow, C | 1 |
| Sonneveld, P | 1 |
| Krug, U | 1 |
| Bone, E | 1 |
| Flores, N | 1 |
| Richardson, AF | 1 |
| Hooftman, L | 1 |
| Jenkins, C | 1 |
| Zweegman, S | 1 |
| Davies, F | 1 |
| Seetharam, M | 1 |
| Tran, M | 1 |
| Xu, L | 1 |
| Renschler, JP | 1 |
| Sridhar, K | 1 |
| Greenberg, PL | 1 |
| Kadia, TM | 1 |
| Shenoy, A | 1 |
| Weinstein, B | 1 |
| Pfannes, L | 1 |
| Loeliger, K | 1 |
| Tucker, Z | 1 |
| Tian, X | 1 |
| Kwak, M | 1 |
| Yong, AS | 1 |
| Maric, I | 1 |
| Scheinberg, P | 1 |
| Groopman, J | 1 |
| Young, NS | 1 |
| Sloand, EM | 1 |
| Mundle, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory Myelodysplastic Syndrome With Ring Sideroblasts (MDS-RS): A Prospective Randomized Controlled Study[NCT06006949] | Phase 4 | 62 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (L[NCT03263091] | Phase 3 | 140 participants (Actual) | Interventional | 2017-09-07 | Terminated (stopped due to Study did not meet its primary efficacy endpoint.) | ||
| A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia[NCT01926587] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Atients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-Based Therapy[NCT02452346] | Phase 2 | 12 participants (Actual) | Interventional | 2015-03-20 | Completed | ||
| Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS[NCT00854646] | Phase 1 | 22 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine[NCT01928537] | Phase 3 | 67 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk[NCT00906334] | Phase 2 | 14 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent[NCT02562443] | Phase 3 | 372 participants (Actual) | Interventional | 2015-12-02 | Terminated (stopped due to Top line analysis indicated that the study had failed to achieve its primary endpoint.) | ||
| Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine[NCT01241500] | Phase 3 | 299 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System[NCT01904682] | Phase 2 | 45 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification[NCT01584531] | Phase 2 | 82 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)[NCT00854945] | Phase 1/Phase 2 | 36 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome[NCT01048619] | Phase 1 | 36 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma[NCT00689000] | Phase 1/Phase 2 | 57 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8[NCT00533416] | Phase 1 | 14 participants (Actual) | Interventional | 2007-09-14 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Survival following treatment to the date of death, assessed up to a period of 3-4 years. (NCT02452346)
Timeframe: from start of treatment until death, assessed up to a period of 3-4 years.
| Intervention | months (Median) |
|---|---|
| All Patients | 15.9 |
6 reviews available for glycine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
Topics: Animals; beta-Thalassemia; Cell Differentiation; Cell Proliferation; Clinical Trials as Topic; Eryth | 2021 |
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Topics: Antineoplastic Agents; Biomarkers; Glycine; Humans; Myelodysplastic Syndromes; Nanotechnology; Neopl | 2013 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Bone Marrow; Cell Cycle Proteins | 2015 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Topics: Azacitidine; Disease Progression; Drug Therapy, Combination; Glycine; Humans; Myelodysplastic Syndro | 2016 |
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibod | 2011 |
New therapeutics for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Bone Marrow; Chromosomes, Human, Pair 5; Glycine; Humans; Hydrox | 2012 |
11 trials available for glycine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelod | 2022 |
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelod | 2022 |
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelod | 2022 |
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Topics: Aged; Anemia; Double-Blind Method; Female; Glycine; Humans; Isoquinolines; Male; Middle Aged; Myelod | 2022 |
Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Glycine; Humans; Leukemia, Myelogenous, Chronic | 2020 |
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy.
Topics: Azacitidine; DNA Methylation; Glycine; Humans; Hydroxamic Acids; Myelodysplastic Syndromes; Treatmen | 2021 |
A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Dru | 2018 |
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Drug Resistance, Neoplasm; Glycine; Humans; Kaplan-M | 2017 |
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biological Availability; Capsules; Disease Progressio | 2013 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; De | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; | 2016 |
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Topics: Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; | 2016 |
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Aminopeptidases; Female; Glycine; Humans; Hydroxamic Acids; Leukemia | 2010 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone Marrow Cells; Chromosomes, Human, P | 2012 |
7 other studies available for glycine and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Targeting ineffective hematopoiesis in myelodysplastic syndromes.
Topics: Aged; Anemia; Blood Transfusion; Disease Management; Female; Glycine; Hematinics; Hematopoiesis; Hum | 2022 |
New Approaches for Anemia in MDS.
Topics: Activin Receptors, Type II; Anemia; Female; Glycine; Humans; Immunoglobulin Fc Fragments; Isoquinoli | 2020 |
Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.
Topics: Antineoplastic Agents; Colchicine; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Gene Expression Re | 2017 |
Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Topics: Animals; Glycine; Hematopoiesis; Hematopoietic Stem Cells; Mesenchymal Stem Cells; Mice; Mice, Trans | 2019 |
Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Line; Female; G2 Phase Cell C | 2014 |
Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase A; Cell Line, Tumor; Cell Proliferation; DNA Damage; | 2015 |
Targeting cyclin D1 for high risk myelodysplastic syndromes.
Topics: Cyclin D1; Female; Glycine; Humans; Male; Molecular Targeted Therapy; Myelodysplastic Syndromes; Sul | 2012 |